相关临床试验
151
140 进行中
药物批准
49
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
137
90.7%
已完成
3
2.0%
尚未招募
3
2.0%
招募中
8
5.3%
- Link Cell Therapies has begun clinical dosing of LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, in a Phase 1 study at MD Anderson Cancer Center. - The trial enrolls patients with advanced or metastatic clear cell renal cell carcinoma, the first clinical test of the company's logic-gating platform. - Link upsized its Series A financing from $60 million to $90 million to fund a second solid tumor program in colorectal cancer with a first-in-human trial planned for 2027. - Jie D'Elia joined as chief executive officer and Friedrich Graf Finckenstein as chief medical officer, while co-founder Brian Slingerland became executive chair.
- Chugai said Roche will discontinue development of the anti-latent myostatin antibody emugrobart in obesity and return all licensed rights to the Japanese originator. - The decision followed an interim analysis of the Phase II GYMINDA study testing emugrobart plus GLP-1/GIP receptor agonists in patients with obesity or overweight. - Chugai concluded that clinically meaningful weight loss was unlikely to be achieved, though emugrobart was well tolerated with no new safety signals. - Chugai has begun preparing to resume development of emugrobart in spinal muscular atrophy and is exploring out-licensing opportunities with third parties.
- Merck reported that its experimental injection Remigromig met the main goal of a 52-week trial in 984 patients with diabetic macular edema. - The drug achieved the required standard for change in visual acuity and was non-inferior to Roche's ranibizumab, an established anti-VEGF treatment. - Remigromig activates the Wnt pathway to restore the retinal blood vessel lining and reduce fluid leakage, but discontinuation rates from retinal vascular complications were higher than with ranibizumab.
- The FDA cleared C2N Diagnostics' PrecivityAD2 and Roche's Elecsys pTau217 plasma test for assessing amyloid pathology in patients with cognitive symptoms. - PrecivityAD2 is the first FDA-cleared Alzheimer's blood test indicated for symptomatic adults aged 40 and older, with 97.6% positive predictive value in validation. - Roche's Elecsys pTau217, developed with Eli Lilly, is cleared for adults 55 and older and runs on the installed cobas laboratory infrastructure.
- Roche will pay Atavistik $70 million upfront with up to $1.9 billion in milestones plus royalties for small molecules designed against several disease targets. - Genentech will pay Earendil $55 million upfront for multiple bispecific antibodies in cancer, in a deal worth over $1.5 billion with royalties. - The agreements are Roche's fourth and fifth announced biotech partnerships in less than a month, following ADC, trispecific and bispecific deals.
- The FDA has granted priority review to the registration application for satralizumab (Enspryng) in MOGAD, an autoimmune disease attacking the myelin sheath of nerve fibres. - The filing rests on Phase III data showing a 68% reduction in relapse risk versus placebo, with 87% of treated patients relapse-free at 48 weeks. - The EMA has validated the European marketing authorisation application for the same indication, with an FDA decision expected by 10 January 2027.
- Earendil Labs will receive a $55 million upfront payment under a research collaboration with Genentech to discover and develop bispecific antibodies in oncology. - Total potential deal value, including development, regulatory and sales milestones plus tiered royalties, exceeds $1.5 billion, with the transaction subject to customary closing conditions. - Earendil leads antibody discovery and research through early clinical development for pre-agreed target combinations, after which Genentech takes over global development and commercialization. - The deal extends Earendil's AI-enabled biologics partnering strategy, following Sanofi collaborations and a $787 million raise to expand a pipeline of more than 40 programs.
- Merck's remigromig met the primary endpoint in the Brunello phase 2b/3 trial, showing noninferiority to ranibizumab on best-corrected visual acuity at Week 52. - The trispecific drug agonizes the Wnt signaling pathway by mimicking norrin, offering a non-VEGF mechanism for diabetic macular edema patients. - Remigromig was well tolerated, but proliferative diabetic retinopathy, vitreous hemorrhage and adverse event-related discontinuations occurred more often than with ranibizumab. - Merck acquired remigromig in its $1.3 billion upfront EyeBio takeover and will present the data at the American Academy of Ophthalmology meeting.
- Roche will pay Atavistik Bio $70 million upfront and up to $1.9 billion in research, development and commercial milestones, plus royalties on approved drugs. - The partnership uses Atavistik's metabolite-protein screening platform to find cryptic binding pockets on proteins that conventional approaches struggle to reach. - Atavistik leads discovery and research while Roche takes over preclinical work, human testing, regulatory filings and commercialization in cardiovascular, renal and metabolic diseases. - Atavistik continues its own rare hematologic programs, led by oral allosteric AKT1 inhibitor ATV-1601 in a phase 1/2 trial for hereditary hemorrhagic telangiectasia.
- Roche's investigational antisense oligonucleotide sefaxersen met the primary endpoint of the Phase 3 IMAgINATION study in adults with primary IgA nephropathy at 37 weeks. - The prespecified interim analysis showed statistically significant and clinically meaningful reductions in 24-hour urine protein-to-creatinine ratio versus placebo, with no new safety signals. - Roche did not disclose the magnitude of the proteinuria reduction, limiting cross-trial comparison with approved and investigational IgAN therapies. - The 459-patient trial remains blinded and will continue to week 105 to assess kidney function change measured by eGFR.
